Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene

Author：                      

Publisher： Spandidos Publications

ISSN： 1021-335X

Source： Oncology Reports, Vol.30, Iss.3, 2013-01, pp. : 1463-1472

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial

By Rossi David  

Targeted Oncology, Vol. 5, Iss. 4, 2010-12 ,pp. : 231-235

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer

By Shim Hyun  

Gastric Cancer, Vol. 14, Iss. 3, 2011-08 ,pp. : 249-256

Springer Publishing Company

Access to resources Recommend Favorite

Predictive factors in patients with EGFR mutationnegative nonsmall cell lung cancer treated with erlotinib

By  

Oncology Letters, Vol. 8, Iss. 6, 2014-01 ,pp. : 2699-2704

Spandidos Publications

Access to resources Recommend Favorite

Selective Intra-arterial Chemotherapy with Floxuridine as Second- or Third-Line Approach in Patients with Unresectable Colorectal Liver Metastases

By Samaras Panagiotis  

Annals of Surgical Oncology, Vol. 18, Iss. 7, 2011-07 ,pp. : 1924-1931

Springer Publishing Company

Access to resources Recommend Favorite

Impact of third-line treatment with irinotecan plus cetuximab on non-tumor standardized uptake values in patients with metastatic colorectal cancer

By        

Oncology Letters, Vol. 4, Iss. 1, 2012-01 ,pp. : 131-134

Spandidos Publications

Access to resources Recommend Favorite